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ABSTRACT
PROPAGATION OF OLIGOMERIC α-SYNUCLEIN AND AMYLOID-β:
IMPLICATIONS FOR PARKINSON’S AND ALZHEIMER’S DISEASES
by Matthew Stephen Planchard
May 2014
The aggregation of amyloidogenic proteins is a critical event in the pathology of a
variety of neurodegenerative diseases, including Alzheimer’s disease (AD) and
Parkinson’s disease (PD). The proteins α-synuclein (αS) and amyloid-β (Aβ) are involved
in the formation of amyloid lesions observed in PD and AD, respectively. Both PD and
AD exhibit a significant amount of co-pathology in clinical settings, and the αS and Aβ
proteins have been shown to interact in vitro. Recent experimental consensus has shown
oligomeric species to be significant, if not primary, sources of toxicity in these diseases.
In this work, the ability of oligomeric species of αS and Aβ to cross-propagate
their oligomeric state was investigated. Oligomeric species of αS were generated in the
presence of dopamine (DA) were characterized. Five discrete and stable dopaminederived αS oligomers (DSOs) ranging from 2-14mers were fractionated. All isolated
DSOs were formed along an off-fibril formation pathway. Their mechanism of formation
was dependent on the oxidation of DA, implicating the quinone form of DA as an inducer
of oligomerization. Importantly, DSOs could self-propagate through interactions with αS
monomers. DSOs could also cross-propagate to Aβ42 monomers, yielding Aβ42
oligomers. In addition, Aβ42 oligomers (LFAOs) were shown to be capable of crosspropagating their oligomeric state to αS monomers. This work provides the first
experimental evidence for the cross-propagation of oligomeric states among
ii

neurodegenerative proteins and provides a potential molecular explanation for the copathology causing increased disease severity in many PD and AD patients.
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CHAPTER I
INTRODUCTION
Parkinson’s Disease
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder
characterized by rigidity, imbalance, tremor, and characteristically altered gait and
posture. PD is characterized by the presence of neuronal intracellular inclusions of the αsynuclein (αS) protein known as Lewy bodies (LBs) or Lewy neurtes (LNs) depending on
their location within neuronal cells.1 Severe cases often lead to cognitive impairment and
dementia, in addition to the more typical motor symptoms.2 PD affects between one and
two percent of all people over 65, making it the most common motor system disorder.3
The primary cause of PD is the death of dopaminergic neurons in the substantia nigra.1
Lewy bodies are found most commonly in the substantia nigra but are also found in
smaller numbers throughout the brain.4 In addition to αS, neurofilament,5 ubiquitin,6 and
p627 are found within Lewy bodies and Lewy neurites.
Although the majority of cases of PD are idiopathic in nature, approximately 5%
are inherited.3 These cases of familial PD provide substantial evidence linking αS to PD
pathology while illuminating the underlying molecular mechanisms of the disease. The
least common monogenic cause of PD was also the first to be discovered: a mutation in
the SNCA gene causes a point mutation in αS, A53T. This causes αS to rapidly
accumulate in LBs and LNs.8,9 Other point mutations (e.g., A30P and E46K) have also
been shown to lead to early-onset PD with dementia symptoms and increased localization
of Lewy bodies in brain regions outside of the substantia nigra,10 while duplications and
triplications of SNCA lead to early and severe cases of PD.11
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α-Synuclein
αS is a protein made up of 140 amino acids, with a molecular weight of
approximately 14.6 kDa. Although it adopts a largely α-helical conformation upon
binding to lipid vesicles, it is an intrinsically disordered protein (IDP) and exists in a
random coil conformation in solution.12 αS is one of three members of the synuclein
family, which also includes β- and γ-synuclein. α- and β-synuclein are primarily found in
the central nervous system, while γ-synuclein is found in the periphery.13,14 The name
synuclein reflects the cellular localization of these proteins at presynaptic termini.14
Functionally, αS seems to play a role in dopamine release from presynaptic termini and
the regulation of the presynaptic vesicle pool.15,16 αS has three regions: the N-terminal
repeat region, the non-amyloid component (NAC) region, and the acidic C-terminal
region.17 The NAC is hydrophobic and stretches from amino acids 61-95, overlapping
with the end of the N-terminal repeat region.18
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease,
affecting 5.4 million people in the United States alone in 2012.19 AD is primarily a
behavioral and cognitive disorder and is characterized by progressively impaired
memory, decreased cognitive ability, confusion, and altered behavior. Although these are
the primary diagnostic characteristics of AD, many patients also develop difficulty with
gait and other motor problems resembling parkinsonism as the disease progresses.20
Unlike PD, which primarily affects a single type of neuron in a particular region of the
brain, AD affects a wide variety of neurons throughout the brain, rendering acetylcholine
replacement therapies largely ineffective.20
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The primary pathological hallmarks of AD are neuritic plaques and neurofibrillary
tangles.21 Neuritic plaques are found in the extracellular space, primarily in the limbic
and association cortices,22 while neurofibrillary tangles are found intracellularly in a
variety of brain regions.23 Plaques are composed primarily of aggregated amyloid β (Aβ)
protein, while tangles are made up of hyperphosphorylated tau protein. Although the
exact molecular cause of AD remains unknown, accumulating evidence suggests that the
aggregation of extracellular Aβ into neuritic plaques is the initiating event in the cascade
leading to other pathological features of AD, including the hyperphosphorylation of tau
and its subsequent association into neurofibrillary tangles.24
Amyloid-β
Aβ is derived from the amyloid precursor protein (APP), a membrane-bound
protein ubiquitously expressed in both neuronal and non-neuronal cells.25 The generation
of Aβ occurs upon sequential cleavage of APP by aspartyl proteases β- and γ-secretase,
leading to the release of Aβ into the extracellular space (Figure 1).26 The function of
extracellularly secreted Aβ has not been concretely elucidated, but APP and its various
cleavage products may be involved in autocrine signaling, protease inhibition, clotting
factor inhibition, or other processes.20 The cleavage of APP by γ-secretase is somewhat
nonspecific, and results in several isoforms of Aβ ranging from 39-43 amino acids in
length. Among these, Aβ40 and Aβ42 are the most abundant. The production of Aβ42 is
increased in all known forms of familial AD caused by mutations in APP or the PSEN
genes.20,27-29 Aβ42 also displays a more rapid aggregation profile compared to Aβ40 and
generally is the first to form plaques.30,31 As with αS, the formation of cross β-sheet-rich
aggregates of Aβ is associated with cellular toxicity.32
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Figure 1. Sequential cleavage of APP by β- and γ-secretase yields Aβ.
Amyloid Proteins in Neurodegenerative Disease
Amyloid Aggregation
Both αS and Aβ are proteins capable of forming amyloid aggregates, which are
accumulations of protein with a fibrillar morphology made up exclusively of β-sheet
secondary structure while also exhibiting characteristic birefringence upon staining with
Congo red dye.33 Along with αS and Aβ, the amyloid aggregation of many proteins is
related to various disease states, including aggregation of the immunoglobulin light chain
(AL amyloidosis), islet amyloid polypeptide (type 2 diabetes), transthyretin (transthyretin
amyloidosis), and prion protein (Creutzfeldt-Jakob disease), to name a few.
Amyloid aggregation is a self-assembly process in which monomers associate
with each other to form insoluble, high molecular weight fibrils. Although aggregation is
affected by conditions such as ionic strength, pH, temperature, and concentration, it
always exhibits a nucleation-dependent mechanism analogous to crystal growth. In this
process, monomers associate with one another in a rate-limiting fashion to form small
aggregates enriched in β-sheet secondary structure. This species may then serve as a
nucleus for further monomer association and aggregation. The rate of post-nucleation
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association is considerably higher, leading to the rapid formation of protofibrils and,
eventually, stable fibrils. This nucleation-dependent aggregation displays a sigmoidal
growth pattern with lag, growth, and saturation phases (Figure 2). The aggregation
process can be hastened by the addition of small quantities of pre-formed aggregates in a
process called seeding, which reduces or eliminates the lag phase of aggregation (Figure
2).

Figure 2. Theoretical amyloid aggregation growth curves for seeded and unseeded
protein.
Amyloid Oligomer Toxicity
In the case of PD and AD, it has long been clear that αS and Aβ, respectively,
play a causative role in the death of neuronal cells. Initially, it was believed that fibrils
were the toxic species in these diseases. However, the correlation between fibril
formation and cell toxicity is inconsistent, and a number of recent studies indicate that
small oligomeric species (~2-30mers) are the primary toxic agents causing neuronal death
and synaptic dysfunction.34,35 In PD, toxic αS oligomers have been shown to accumulate
within the ER in both mice and humans.36 In addition, the forced dimerization of αS
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protein was shown to cause significant cell toxicity.37 Large αS oligomers (>200 kDa)
were also shown to inhibit SNARE-mediated vesicle lipid mixing in neuronal cells,
potentially preventing dopamine release and causing toxicity.38 In AD, as well, numerous
studies have shown oligomers to be significantly more toxic than fibrils.39,40
Interfacial Aggregation and Off-fibril Formation Pathways
Oligomers are typically low molecular weight intermediates along the fibril
formation pathway. However, significant data has emerged that suggest oligomers may
also be generated in such a way that they proceed slowly or not at all towards fibrils,
making them off-pathway oligomers.41-44 This is especially true in the case of aggregation
in the presence of interfaces. Work in the author’s lab has previously utilized micellar
interfaces to generate a stable, isolable Aβ42 oligomer termed LFAO (large fatty-acidderived oligomer) that remains in the oligomeric state for an extended period of time,
only slowly converting to fibrils.43 Other labs have used alternate methodologies to
generate similarly stable oligomeric Aβ42 species,40,45 and stable oligomers of αS have
been reported by several researchers, as well.46-48 The existence of off-pathways of
aggregation is likely due to the presence of kinetic traps along the energy landscape
toward fibril formation, in which the relative stability of trapped oligomers necessitates
overcoming additional energy barriers in order to further aggregate toward fibril
formation. This may be due to slightly different secondary and tertiary structures within
off-pathway oligomers, with off-pathway oligomers exhibiting antiparallel or out-ofregister β-sheets (as opposed to the parallel, in-register β-sheets found in fibrils).41,44
Physiologically, such oligomers may represent a persistent source of toxicity due to their
increased half-lives. In addition the overall assembly of off-pathway oligomers may be
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subtly different from those formed along the fibril formation pathway and may represent
different conformational variants with distinct biochemical and cellular properties.
Prion-like Self-propagation
Prion protein (PrP) is an amyloid protein, and its self-propagation is well-known.
Essentially, toxic, misfolded prion protein, PrPSc, is capable of interacting with normal,
cellular prion protein, PrPC, in a template-assisted corruptive mechanism while promoting
the native protein’s conversion to a misfolded, toxic state. Thus, the population of PrPSc
continually increases, causing the neuronal death seen in Creutzfeldt-Jakob disease and
other prionopathies such as scrapie and mad cow disease. This type of template-assisted
corruptive mechanism is not only seen with prion protein, however. In fact, the meaning
of the term prion has recently broadened to refer to any protein capable of propagating its
conformational state.49 This prion-like propagation has been observed for both αS and
Aβ. For example, fibrillar αS has been shown to propagate itself from neuron to neuron
via anterograde transport.50
Similar observations have been made for Aβ. 51 To date, molecular studies of selfpropagation in αS and Aβ have been somewhat more limited. Aβ was shown to have a
variety of different fibril morphologies upon its aggregation, and these were shown to
propagate upon seeding of fresh monomer.52 A FRET study using labeled αS oligomers
indicated that monomer aggregation in the presence of the oligomers involved a specific
conformational change that was accelerated in the presence of the oligomeric species.53
Work in the author’s lab indicated that LFAOs were capable of self-propagating their
oligomeric state when they were used as seeds with fresh Aβ42 monomer.54
Amyloid Cross-seeding and Cross-propagation
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The process of amyloid aggregation can be made to occur more quickly through
the inclusion of preformed fibrillar seeds in the reaction mixture. However, this property
is not necessarily limited to seeds of the same type as the monomeric protein. Functional
curli protein from various bacterial species, sharing less than 30% sequence identity, are
able to cross-seed each other’s aggregation in mixed-growth colonies and promote the
formation of interspecies biofilms.55 The formation of human αS fibrils can be seeded by
preformed fibrils of E. coli GroES, hen lysozyme, and bovine insulin.56 It is possible that
cross-seeding occurs due to the broad similarities among amyloid fibril structures and
interactions among the core, amyloid-forming regions of each protein, a hypothesis
supported by the finding that the microtubule protein tau was capable of forming fibrils
when its core fibrillization motifs was replaced with the amyloidogenic regions from
prion protein, αS, and Aβ.57 In addition to cross-seeding, some combinations of amyloid
species are capable of cross-propagation, which is a distinct phenomenon involving the
transfer of the specific conformational state of one protein to another protein of divergent
sequence or structure. For example, bovine and mutated human insulin, which have
differing spectral features upon their solitary aggregation, display faithful transmittance
of the spectral properties of the seed protein when one is used to seed the other.58 The
injection of heterogeneous, aggregated αS from Lewy bodies into human brains,
recombinant human αS, or recombinant mouse αS induced αS pathology in wild-type
mice.59 Importantly, this pathology spread throughout the brain, and, in the case of
injections with human αS, the human αS aggregates disappeared over time, while mouse
αS aggregates appeared, indicating that the human αS aggregates promoted the
aggregation of mouse αS. Preliminary work from the author’s lab, not included in this
study, indicates that oligomeric Aβ42 (LFAOs) are capable of promoting the formation of
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oligomeric Aβ40 and mutant Aβ42 of a similar molecular weight to the parent LFAO
(unpublished data). The idea that prion-type self-propagation mechanisms may underlie a
variety of neurodegenerative diseases has prompted discussion of a common structural
target for immunotherapy.60
Connections Between Parkinson’s and Alzheimer’s Diseases
Although AD and PD are separate diseases with differing symptoms and
diagnoses, there is a surprising amount of evidence linking the two. As mentioned above,
as PD progresses, dementia and cognitive impairment arise along with the more
characteristic motor symptoms. Approximately 60% of PD patients with dementia exhibit
substantial Aβ deposition upon autopsy.61 In addition, approximately 50% of cases of AD
occur with significant Lewy body pathology.62,63 Genetic studies investigating the effect
of combined αS and Aβ pathology in mice indicated a synergistic relationship between
the two, in which they promote each other’s deposition.2,64 This relationship is borne out
in human patients, in whom the presence of combined AD and PD pathology is
associated with a more aggressive disease progression.65 In patients with PD,
cerebrospinal fluid (CSF) concentrations of Aβ correlate with PD-associated brain
changes.66 Interestingly, CSF levels of αS correlated significantly with the presence of
mild cognitive impairment or AD in another group of patients.67 In addition to clinical
evidence, molecular evidence clearly shows that Aβ and αS are capable of cross-seeding
each other’s aggregation.68 Given the clinical links between PD and AD, the
commonalities in their mechanisms, and the molecular evidence of interactions between
their respective pathogenic proteins, it is likely that the two diseases promote each other’s
development, creating a vicious cycle in which the aggregation of αS promotes the
aggregation of Aβ and vice-versa. Cross-seeding and cross-propagation provide a
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potential molecular link between PD and AD. However, while cross-seeding has been
soundly demonstrated, it is unclear whether oligomeric species, which are the most toxic
in these diseases, are capable of cross-propagating their toxic state to other
neurodegenerative proteins.
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CHAPTER II
HYPOTHESIS, OBJECTIVES, AND POTENTIAL IMPLICATIONS
Primary Goal: Investigation of Cross-propagation between Amyloid-β and α-Synuclein
The primary goal of the present study is to investigate potential cross-propagation
between αS oligomers and Aβ42 monomers, as well as Aβ42 oligomers and αS
monomers. The hypothesis is that both αS and Aβ42 oligomers will be able to recruit
monomers of the complementary protein into oligomeric assemblies (Figure 3).

Figure 3. Schematic of cross-propagation. The characteristics of the parent oligomer are
retained as the oligomeric state is propagated across protein species.
To investigate this hypothesis, αS oligomers will be generated by incubating
monomeric αS with dopamine (DA) as has been previously reported.46,69 If possible, αS
oligomers will also be generated through incubation with fatty acids, using a method
similar to that used in this lab to generate Aβ oligomers.43 αS oligomer cross-propagation
with Aβ42 monomers will be investigated through immunoblotting and fluorescence
assays. The cross-propagation of Aβ42 oligomers will be analyzed in a similar fashion,
with oligomers being generated as previously described.43
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Secondary Objectives
Dopamine-derived αS Oligomer (DSO) Characterization
Size-exclusion chromatography (SEC) will be used in an attempt to isolate
discrete αS oligomers. Although DSOs have already been shown to be isolable, they have
only been partially characterized.69 Rigorous characterization will be performed using
biophysical methods including western blotting, dynamic light scattering (DLS), circular
dichroism (CD), and atomic force microscopy (AFM). In addition, their capacity to selfpropagate their oligomeric state with αS monomers will be determined. The author will
also investigate the mechanism of αS oligomer formation, specifically whether oxidation
of αS and DA specifically induces oligomers as has been previously observed.70-72
Potential Implications
This work has the potential to contribute to the overall study of both PD and AD
in several ways. First, and most importantly, it stands to provide a potential molecular
link between the combined pathologies often seen in these two disorders. The elucidation
of such a link would pave the way towards discovering therapeutic targets for preventing
the cross-propagation of these diseases, or even treating or preventing both diseases
simultaneously. Second, this study stands to contribute to the existing scientific literature
on αS oligomers, both in the potential generation of αS oligomers through incubation of
fatty acids and through further isolation and characterization of αS oligomers generated in
the presence of DA and their mechanisms of formation. These dopamine-derived
oligomers, in particular, have considerable physiological relevance given the role of αS in
DA release.
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CHAPTER III
MATERIALS AND METHODS
Materials
Amyloid-β (Aβ) 42 was synthesized by the Peptide Synthesis Facility at the Mayo
Clinic (Rochester, MN) using routine Fmoc chemistry. MALDI-ToF mass spectrometry
showed greather than 90% purity of the peptide. Ab5 monoclonal primary antibody was
obtained from the Mayo Clinic (Jacksonville, FL). Syn211 monoclonal primary antibody
was obtained from Sigma® (St. Louis, MO), and lauric acid (C12) was purchased as a
sodium salt from NuCheck Prep, Inc. (Elysian, MN). All other chemicals and equipment
were purchased from VWR, Inc., unless otherwise indicated.
Amyloid-β Purification
To purify Aβ42, 0.5-1.5 mg of crude peptide was dissolved in 35 µL 0.5 M
NaOH, followed by immediate dilution to 500 µL for a final concentration of 35 mM
NaOH. After 15 minutes, this solution was loaded onto the fast protein liquid
chromatography (FPLC) system, using 20 mM Tris, pH 8.0 through a Superdex 75
column with a flow rate of 0.5 mL/min and collecting 0.5 mL fractions. The protein
eluted between fractions 24 and 27. Concentrations were determined via UV-Vis
spectroscopy using a molar extinction coefficient at 276 nm of 1450 M-1cm-1 (expasy.org)
with a baseline correction with 20 mM Tris, pH 8.0. Aβ42 was stored at 4 °C and was
used within three days of purification to prevent the formation of aggregates.
Oligomer Generation and Isolation
α-Synuclein Oligomer Generation
Fatty acid-derived oligomers. αS (25 or 50 µM) was incubated with varying
concentrations of lauric acid (C12), along with 50 or 150 mM NaCl, in 20 mM Tris, pH
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8.0. Samples were incubated at 37 °C, either quiescent or agitated and analyzed by
polyacrylamide gel electrophoresis (PAGE) and silver staining to determine the presence
of oligomers. This experiment was replicated three times to ensure the homogeneity of
results.
Dopamine-derived αS oligomers. αS (50 µM) was incubated with a fourfold molar
excess of dopamine (DA), along with 50 mM NaCl, in 20 mM Tris, pH 8.0. The solution
was kept at 37 °C with constant agitation for 72 h, after which it was centrifuged at
18,000 x g for 20 minutes. The supernatant was loaded onto the FPLC system using 20
mM Tris, pH 8.0 through a Superdex 200 column (GE Life Sciences) with a flow rate of
0.2 mL/min, and 0.5 mL fractions were collected. Oligomers eluted in fractions 18
through 25, and their presence was confirmed through PAGE followed by silver staining
or western blotting. Oligomers were kept at 4 °C and used within five days. The
concentration of dopamine-derived αS oligomers (DSOs) was estimated via UV
spectroscopy using a molar extinction coefficient at 276 nm of 5600 M-1cm-1.
Amyloid-β Oligomer Generation
Large, fatty acid-derived oligomers (LFAOs) were generated as previously
described.43 Briefly, Aβ42 (50 µM) was incubated in 20 mM Tris, pH 8.0, with 50 mM
NaCl and 5 mM C12 at 37 °C for 48 h. The solution was then centrifuged for 20 minutes
at 18,000 x g, and the supernatant was purified via FPLC using 20 mM Tris, pH 8.0,
through a Superdex 75 column (GE Life Sciences) with a flow rate of 0.5 mL/min,
collecting 0.5 mL fractions. LFAOs eluted between fractions 16 and 19, and
concentrations were estimated using UV spectroscopy with a molar extinction coefficient
at 276 nm of 1450 M-1cm-1. LFAOs were kept at 4 °C and used within three days of
purification.
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Self-propagation of DSOs
For self-propagation reactions, solutions containing 50 µM αS, 0.1 µM DSO, 50
mM NaCl, and 0.01% NaN3 in 20 mM Tris, pH 8.0 were incubated at 37 °C in quiescent
conditions. An αS control containing no DSO was incubated along with the experimental
samples. In addition, for western blots, DSO controls for each oligomer size were made
with 0.1 µM DSO and no αS. These controls were kept at 4 °C since their purpose was
only to provide a measure of the initial amount of DSO included in the reaction. Samples
were monitored by ThT fluorescence intermittently and analyzed via gel electrophoresis
and western blotting with Syn211 primary antibody at 72 and 144 h. This experiment was
performed five times to ensure reproducibility and reliability of results.
Cross-propagation Reactions
DSO Cross-propagation with Amyloid-β Monomer
To examine the cross-propagating ability of αS oligomers with Aβ42 monomers,
15 µM Aβ42 monomer was incubated with 50 mM NaCl, 0.01% NaN3, and 1 µM DSO,
quiescent at 37 °C, for 72 h. ThT fluorescence was monitored daily, and western blots
using Ab5 primary antibody were used to visualize oligomer formation. This experiment
was performed five times to ensure reproducibility. A negative control for the primary
antibody was performed using the same concentrations of oligomers in the absence of
Aβ42 to ensure that no cross-reactivity was occurring.
LFAO Cross-propagation with α-Synuclein Monomer
For cross-propagation experiments with LFAOs and αS monomers, 10 µM αS
monomer was incubated with 50 mM NaCl and either 5, 2.5, or 1 µM LFAO in 20 mM
Tris, pH 8.0, and agitated at 37 °C for 72 h. Controls of αS monomer alone and LFAO
alone were also incubated under the same conditions. Western blots using Syn211 and
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Ab5 primary antibodies were used to visualize oligomer formation. This experiment was
performed three times to ensure data reliability. A negative control for Syn211 against
LFAO was performed using equivalent oligomer concentrations in the absence of αS
monomer, to ensure a lack of cross-reactivity.
Characterization Methods
Polyacrylamide Gel Electrophoresis (PAGE)
Protein solutions were mixed with Laemmli sample buffer (Biorad) in a 1:3 ratio,
unless otherwise noted, and loaded onto Biorad Mini-PROTEAN® 4-20% precast gels.
The gels were run in a Biorad Mini-PROTEAN® tetra cell in 1X Tris-glycine-SDS buffer
at 160 V for approximately 45 minutes. Novex® Sharp prestained or unstained standards
(Life Technologies™) were used as molecular weight standards.
GelCode Blue Staining
Immediately following electrophoresis, gels were washed two times for five
minutes each in nanopure water. GelCode Blue stain (Thermo Scientific) was applied to
gels for approximately one hour, after which a one hour wash with nanopure water was
used to destain the gel. White light images were taken on a GelDoc molecular imager
(BioRad).
Silver Staining
The Pierce silver stain kit (Thermo Scientific) and associated protocol were used
for silver stains. To summarize, after electrophoresis, gels were washed twice for 5 min in
nanopure water, followed by two 15 minute washes in fixing solution of 30% EtOH and
10% acetic acid and two 5 minute washes in a wash solution of 10% EtOH. The gel was
then sensitized for 1 minute using the provided sensitizer solution and washed twice for 1
minute each with water. The gel was then stained with the provided stain solution for 30
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minutes, followed by two 20 s washes with water. The gel was then developed using the
provided developer solution until the band intensity reached the desired level, at which
point the developing process was stopped with 5% acetic acid. White light images were
taken on a GelDoc molecular imager (Biorad).
Western Blotting
Following electrophoresis, proteins were elctroblotted onto BioTrace™ NT
nitrocellulose transfer membrane (Pall Corporation) at 100 V for 60 min in transfer buffer
containing 100 mM Tris, 0.76 M glycine, and 20% MeOH. The blots were then boiled in
1X PBS for 2 min, following which they were blocked from 1 h through overnight in
blocking buffer containing 5% nonfat dry milk and 0.1% Tween®-20 in 1X PBS (1.76
mM KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, and 137 mM NaCl, pH 7.4). Blots were
then incubated for 3-12 h in a primary antibody solution containing 0.5 µg/mL of either
Syn211 (for αS blots) or Ab5 (for Aβ blots) primary antibody in 10% (v/v) transfer buffer
in 1X PBS. Blots were then subjected to two 5 minute washes in 1X PBS, after which
they were incubated in a solution of horseradish peroxidase conjugate anti-mouse
secondary antibody containing 0.7 µg/mL antibody in 11% (v/v) transfer buffer in 1X
PBS. After 45 minutes, blots were subjected to four 5 min washes in 1X PBS, followed
by development with Pierce ECL western blotting substrate (Thermo Scientific) and
visualization on a GelDoc molecular imager (Biorad).
Thioflavin T Aggregation Assay
For Thioflavin T (ThT) fluorescence assays, protein solutions were diluted 15fold using a solution of 10 µM ThT in 20 mM Tris, pH 8.0 in a quartz microcuvette.
Samples were allowed to equilibrate for 30 s prior to monitoring in a Cary Eclipse
fluorescence spectrophotometer (Varian, Inc.). Continuous fluorescence measurements
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were taken for 1 min with excitation and emission wavelengths set at 450 and 482 nm,
respectively. Both excitation and emission slits were set at 10 nm. The average
fluorescence value over the 1 min period was taken as the fluorescence value for a
particular point. Where noted, ThT data was fitted to a Boltzman sigmoidal equation,
shown below, where F is fluorescence intensity, A1 and A2 are fixed parameters, and t0.5
is the time required to reach half saturation of ThT fluorescence. Lag times for fitted
curves were equal to t0.5 – dt.
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Dynamic Light Scattering
Dynamic light scattering (DLS) measurements were made using a Zetasizer Nano
S (Malvern Inc., Worcestershire, UK) in a quartz microcuvette (Hellma). Samples were
measured for 60 measurements of 30 s each with a pre-equilibration time of 60 s.
Following measurement, sample number (%) and size (d.nm) were exported and plotted.
Circular Dichroism
CD measurements were made on a Jasco J-815 specropolarimeter (Jasco, Inc.
MD). Samples were monitored in continuous scan mode from 260-190 nm in a 0.1 cm
path-length quartz cuvette (Hellma). Acquisition parameters were 50 nm/min with 8 s
response time, 1 nm bandwidth, and 0.1 nm data pitch. Data sets were averaged over two
scans.
Atomic Force Microscopy
AFM was performed in collaboration with Dr. Sarah Morgan’s research group
(USM School of Polymer Science). Oligomeric samples were prepared for AFM by
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diluting them 100x in 20 mM Tris, pH 8.0. Monomer and fibril samples were diluted to 1
M, also in 20 mM Tris, pH 8.0 prior to plating.
For sample preparation, cleaved mica was loaded with 100 µL of APTES solution
(500 µL APTES and 50 mL of 1 mM glacial acetic acid) for 15 minutes. Subsequently,
the APTES solution was decanted, and the mica was washed 4x with 150 µL of DI water,
dried with nitrogen gas, and stored in a desiccator for one hour. To fix the peptide, mica
was loaded with 150 µL of 0.1 - 0.25 uM peptide sample for 20 minutes. Once again, the
wafers were decanted, rinsed 4x with DI water, dried with nitrogen gas and stored in the
desiccator until imaged.
Imaging was done under ambient conditions on a Dimension Icon with ScanAsyst
AFM (Dimension Technologies) in tapping (alternating current mode) using
SCANASYST-AIR silicon probes (length: 600 nm, nominal force constant: 0.4 N/m, and
resonance frequency: 50-90 kHz) (Veeco Instruments). The scan rate was held constant at
0.431 Hz and each image (512x512 data points) was flattened and analyzed using
Nanoscope Analysis software.
Mass Spectrometry
For MALDI-ToF mass spectrometric analysis, samples were plated onto an MSP
AnchorChip 600/96 microScout Target (Bruker Daltonics®). Sample matrix was
prepared with 2.5% (w/v) sinapinic acid in 50% (v/v) acetonitrile with 0.5% TFA (v/v).
When spotting samples, 1 µL of matrix was spotted onto the plate, followed by 1 µL of
sample. Bruker’s protein calibration standard I was also spotted for calibration of the
instrument. The plate was allowed to air dry in a dust-free environment. Measurements
were taken on a Bruker Microflex MALDI-ToF spectrometer using Flex Control
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software. The instrument was used in linear mode with positive polarity, while using
voltage gating to suppress matrix signals below 3,000 m/z. Calibration was performed
using the cubic enhanced algorithm. Flex Analysis software (Bruker) was used to assign
m/z values to mass peaks and to export data.
Data Analysis
All data was collected using proprietary software provided with the measurement
devices. Numerical data manipulation, statistical analysis, and plotting were using
OriginPro 8.5 software (OriginLab). Gel image analysis and manipulation was performed
using QuantityOne 1-D Analysis Software (Biorad). Image manipulation was limited to
cropping, alignment, rotation, and contrast adjustment. Figures were prepared for
publication using Pixelmator 3.1 (Pixelmator Team, Ltd., Vilnius, Lithuania).
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CHAPTER IV
α-SYNUCLEIN PROTEIN PURIFICATION
There are a number of purification protocols for αS present in the literature.
However, a purification protocol for the plasmid construct used in this work has not
previously been reported. Although the protein had been expressed with reasonable
yields, no standardization of the purification protocol had been performed to ensure that
isolated protein was in the monomeric state. Monomeric protein, however, is essential for
accurate determination of lag times and for detailed studies investigating the aggregation
potential of amyloid proteins. It was therefore essential that the method of purification be
standardized in such a way as to produce pure, monomeric αS. The standardized methods
are described in detail below.
Results
α-Synuclein Culture Growth, Purification, and Characterization
Cell growth. The original αS plasmid in pTYB1 (New England Biolabs ®) was
obtained from Dr. Shu-Hui Yen of the Mayo Clinic (Jacksonville, FL). A pTYB1 plasmid
(New England Biolabs®), containing recombinant human α-synuclein (αS), an intein tag
with a chitin-binding domain, and antibiotic resistance genes for ampicillin and
chloramphenicol, was obtained from Dr. Shu-Hui Yen. The plasmid was transformed into
Rosetta™ 2 pLysS Escherichia coli (EMD Millipore®), which are designed to facilitate
the expression of eukaryotic codons rarely used in E. coli. Cells were grown in lysogeny
broth (LB) media until their optical density was between 0.6 and 0.8, at which point they
were induced with 0.7 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 23 °C for 20
h. The cells were then pelleted at 15,000 x g, and the supernatant was discarded. Cells
were resuspended in lysis buffer containing 20 mM Tris buffer, 100 mM NaCl, 1 mM
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EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 0.5% Triton™ X-100 at pH
8.5 and sonicated on ice using 20 s bursts of sonication followed by 60 s of rest for at
least five cycles. The sonicated cells were centrifuged at 9,300 x g for 35 minutes, and the
supernatant was collected.
Protein isolation. Purification then followed the IMPACT™ system protocol
(New England Biolabs®), performed entirely at 4 °C (Figure 4).

Figure 4. Schematic of purification of αS plasmid construct via the IMPACT™ protocol.
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Briefly, a Kontes® chromatography column containing approximately 10 mL of chitin
resin was equilibrated using 100 mL of column buffer (20 mM Tris, 100 mM NaCl, 1
mM EDTA, 0.5% Triton™ X-100, pH 8.5). The supernatant was then loaded onto the
column and allowed to run through at a rate of approximately one drop every four
seconds. The column was washed with 200 mL of column buffer, followed by a quick
wash with 50 mL of cleavage buffer (20 mM Tris, 100 mM NaCl, 1 mM EDTA, 50 mM
DTT, pH 8.5). The column was left at 4 °C for two days to allow the cleavage reaction to
proceed to completion. The protein was eluted in two 12 mL fractions using 24 mL of
elution buffer (20 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 8.5). Ideally, the protein
should have eluted alone, while the ~55 kDa intein tag remained bound to the column,
but residual intein and some uncleaved protein were sometimes seen in purification gels
(Figure 5). It is also worth noting that αS has a tendency to show up in gel
electrophoresis at ~17-19 kDa, in spite of its molecular weight of 14.46 kDa, due to it
being an intrinsically disordered protein. In fact, αS was originally reported to be a 19
kDa protein.73
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Figure 5. αS purification via the IMPACT method. Lane 1 is SN flowthrough; lane 2 is
CB wash; lane 3 is CLB flowthrough; lanes 4 and 5 are E1 and E2 concentrates,
respectively, showing residual intein and other contaminants; lanes 6 and 7 are E1 and
E2, respectively, prior to filtration; and lanes 8 and 9 are E1 and E2 filtrates
(representative data of n > 10).
To ensure the removal of these contaminants, the eluate was filtered using a 30
kDa nominal molecular weight limit (NMWL) Amicon® Ultra Centrifugal Filter (EMD
Millipore®) to remove any residual intein tag (Figure 6). The filtrate was then dialyzed
against a 10 kDa molecular weight cutoff (MWCO) Spectra/Por® 6 dialysis membrane
for a total dilution factor of approximately 4x109. The dialyzed solution was then
evaporated in a Vacufuge Plus (Eppendorf). Typical yield for 1 L of cells was ~8-10 mg
of protein. The resultant dry protein was resuspended in 4 mL of hexafluoro-2-propanol
(HFIP), which was then evaporated to a thin film in the vacufuge. HFIP films were stored
at -20 °C until use.
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Figure 6. Schematic of isolation of αS from column eluate.
SEC purification. To ensure only monomeric αS was used in experiments, HFIP
films stored at -20 °C were further purified via SEC. Films were dissolved in 35 µL 0.5
M NaOH, followed by immediate dilution to 500 µL in nanopure water, for a final
concentration of 35 mM NaOH. The protein was left in this solution for approximately 15
minutes before being purified on an ÄKTApurifier FPLC system (GE Healthcare) using
20 mM Tris, pH 8.0 as the elution buffer through a Superdex 75 column with a flow rate
of 0.2 mL/min and collecting 0.5 mL fractions while monitoring the UV absorbance at
215 and 280 nm. Aggregated αS eluted at fraction 15, and monomers eluted between
fractions 18 and 20 (Figure 7). Note that a double band was seen for some αS fractions,
but this is probably due to the intrinsically disordered nature of αS, as no corresponding
peak was seen in mass spectra. Protein-containing fractions were collected, and
concentrations were measured via UV absorbance with a molar extinction coefficient of
5600 M-1cm-1 at 276 nm (expasy.org), and stored at 4 °C. Monomeric protein retention
compared to the total amount of protein loaded was approximately 60%. Fresh αS was
used within five days of purification to avoid the presence of preformed fibrils and
excessive breakdown into its autoproteolytic fragments.74
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Figure 7. αS SEC elution profile and silver stain. (A) shows the SEC elution profile of an
αS HFIP film. Fractions 15-20, indicated by the dashed lines, were subjected to SDSPAGE and silver stained (B). In B, lanes 1-6 correspond to fractions 15-20, respectively,
with lanes 5 and 6 showing pure αS monomer (representative data of n > 10).
Characterization of αS. Monomeric αS was regularly analyzed via mass
spectrometry. A representative scan is shown in Figure 8, showing monomeric αS at 14.5
kDa. In addition, far-UV circular dichroism (CD) and ThT fluorescence were employed
to analyze the aggregation of αS (8.67 µM) agitated at 37 °C for 212 h in 20 mM Tris, pH
8.0, with 50 mM NaCl. As expected, monomeric αS displayed a CD spectrum
characteristic of random coil conformation when freshly purified (Figure 9A, solid line),
which converted to β-sheet conformation with a minimum at 216 nm after 212 h,
indicating aggregation (Figure 9B, dashed line). The average fluorescence of three
samples of αS agitated in 20 mM Tris, pH 8.0, at 37°C with 50 mM NaCl is shown
below. Aggregation occurred as expected, with the growth fitting a sigmoidal Boltzman
equation with an adjusted R2 of 0.979 indicating a lag time of approximately 50 h.
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Figure 8. Mass spectrum of monomeric αS. Monomeric αS is seen at 14.4 kDa, along
with autoproteolytic fragments at 7.3 kDa and ~12 kDa (representative data of n > 10).

Figure 9. αS aggregation. (A) shows CD spectra of monomeric (solid line) and
aggregated (dashed line) αS, indicating a clear shift toward β-sheet structure
(Representative data of n=3). (B) shows ThT fluorescence over time of aggregating αS
(n=3).
Autoproteolytic fragmentation of αS
In addition to monomeric αS, MALDI-ToF data also indicated the presence of
some smaller fragments at 7.3 and 12.2 kDa. Initially, the fragment was suspected to be a
peak resulting from doubly charged αS species; however, analysis of the peak mass from
several experiments showed it to be slightly more than half the mass of the monomeric
protein. In addition, a band at ~7 kDa was seen on SDS-PAGE gels after some incubation
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time. A variety of purification techniques were performed in an attempt to further purify
samples, but the fragments remained (data not shown). In spite of their prevalence in the
mass spectrum, these fragments were not detectable in silver stains or western blots of
freshly purified monomer (e.g. Figure 7B); however, αS left at 4 °C for extended periods
or incubated at 37 °C developed obvious 7 kDa bands in silver stains (e.g. FiguresFigure
10 and Figure 21). The work of Vlad and colleagues demonstrated the autoproteolytic
activity of αS, which produces a major fragment of 7 kDa and several minor fragments,
including one with a molecular weight of 12 kDa.74 Due to the exact matches between the
masses seen in the mass spectra and those reported by Vlad and colleagues, along with
the increase in SDS-PAGE band intensity over time, this autoproteolytic activity was
determined to be the source of the smaller bands. However, the autoproteolytic activity of
αS does not seem to be widely known or reported, as the majority of publications
describing the purification and incubation of αS fail to report the major 7 kDa
autoproteolytic fragment. When stained αS gels are shown, they tend to be truncated at
~15 kDa, or no 7 kDa band is present. To determine whether this was a byproduct of
staining methodology, GelCode Blue stain, silver stain, and western blotting were used to
visualize the 7 kDa band in 10 µM αS monomer left at 4 °C for one month (Figure 10).
While the band was clearly visible using silver stain, it was not evident when gels were
developed using GelCode or western blotting. In the case of GelCode, the band was not
visible at typical working concentrations of protein due to the stain’s lack of sensitivity,
but SDS-PAGE analysis of a highly concentrated sample (90 µM) revealed the 7 kDa
band (data not shown).
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Figure 10. Visualization of the 7 kDa αS autoproteolytic fragment. Comparison of 7 kDa
band using silver stain (Ag), GelCode blue (GC), and western blotting (WB).
Representative of n=3.
Mass Spectrometric Quantification of αS Monomer
Given the autoproteolytic activity of αS, the incubation of monomer over time
would lead to a decrease in the monomeric concentration. If the concentration of a sample
is determined through standard methods (e.g. UV or BCA), the concentration could be
inaccurate due to interference from the 7 kDa or other autoproteolytic fragments. In order
to determine whether mass spectrometry could be used to accurately determine the
original concentration of αS monomer in a sample, mass spectra were obtained for
samples left at 4 °C for three days after their initial concentrations were determined via
UV-Vis. When various combinations of peak intensities and ratios were plotted against
αS concentration, it was clear that peak intensity alone could not accurately predict αS
concentration (Figure 11A), with adjusted R2 values of 0.307 for the 14 kDa peak (■) and
-0.182 for the 7 kDa peak (●). However, when the ratio of the intensity of 14 kDa peak to
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that of the 7 kDa peak was calculated, it was found to correlate to αS concentration quite
well, with an adjusted R2 of 0.984 (Figure 11B).

Figure 11. Mass spectrometric determination of αS monomer concentration. (A) Intensity
of 14 kDa (■) and 7 kDa (●) peaks does not correlate with αS concentration. (B) The ratio
of 14 kDa to 7 kDa peak intensity correlated very well with αS concentration (adjusted R2
0.984). Representative of n=3.
Knowing that the reaction leading to the formation of the 7 kDa should be zero order
given its autoproteolytic nature, it was assumed that the ratios of signal intensities seen in
the mass spectrum could be due to a consistent concentration of the 7 kDa band,
regardless of initial monomer concentration. Normalization of the intensities of the mass
spectrum for each concentration was, therefore, performed based on the 7 kDa peak by
arbitrarily setting its intensity to 100 a.u. and adjusting the 14 kDa peak intensity
correspondingly. The normalization produced a plot virtually identical to the plot in
Figure 11B, with an adjusted R2 of 0.984 (Figure 12) and a linear equation seen below.
Adjusted absorbance = 1.6884[αS]!+ 0.1079
Therefore, provided a calibration curve can be established, an accurate determination of
initial monomer concentration can be obtained through mass spectrometry alone. Future
experiments will be needed to examine the strength of the calibration curve over time at
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different ranges of concentration, but the sensitivity of mass spectrometry may provide a
means of quantifying monomeric αS at levels below the detection limit of more
traditional methods such as UV-spectroscopy.

Figure 12. Adjusted intensities of the 14 kDa peak when normalized to the 7 kDa peak.
Conclusions
αS Expression and Purification
Although several methods for purifying αS have been reported, a number of these
methods do little to ensure the absence of smaller preformed oligomers in samples of
monomeric αS,75-77 which, due to their capacity to seed aggregation, can significantly
affect lag times and alter aggregation profiles. Given the requirement for consistent lag
times in the interpretation of many experiments performed in this work, a purification
protocol yielding monomer exclusively was absolutely essential. To that end, the above
protocol was developed and standardized.
It is clear that the purification method used in this work generates monomeric αS
in concentrations sufficient for all experiments. The monomeric nature of the protein and
absence of oligomers were confirmed through SDS-PAGE electrophoresis with silver
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staining, indicating with high sensitivity that no contaminating fragments, oligomers, or
residual tags were present in purified monomer. The confirmation of molecular weight
through MALDI-ToF mass spectrometry indicated that αS was not modified in any way
by the purification process, and CD confirmed that the purified protein exhibited the
expected random coil conformation for IDPs.
The amyloidogenicity of the αS produced was also confirmed, using both ThT
fluorescence and CD spectroscopy. When aggregated at 37 °C, αS aggregated in the
expected sigmoidal fashion within 100 h, with lag times varying to a small degree due to
the inherently stochastic nature of the aggregation process. The increase in ThT
fluorescence indicated an increase in β-sheet content, which was further confirmed
through the shift in the CD spectrum of αS. CD showed conversion from a random coil to
a predominantly β-sheet conformation as aggregation progressed.
The rigor of the purification methods used here also allowed for an investigation
of the autoproteolytic properties of αS, which are seldom commented upon in the
literature. It appears as though this reaction is enhanced at high temperatures and at high
ionic strengths (refer to Chapter V, Figure 21 for ionic strength results) but does occur to
a significant degree given enough time at 4 °C. However, the ability to discern the major
proteolytic product (the 7 kDa band) via gel electrophoresis and staining is highly
dependent upon the method of staining. While silver staining is sensitive enough to detect
the band typical working concentrations, GelCode blue was unable to do so. In order to
detect the 7 kDa band using GelCode, a significantly more concentrated sample had to be
used. In addition, western blots using the Syn211 monoclonal antibody never showed the
presence of the 7 kDa band, suggesting that the epitope for the antibody could lie outside
of that region. This helps to explain why the 7 kDa band is seldom seen in published
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work on αS, with some exceptions.36,46,64 Previous work by Vlad et al. showed the variety
of autoproteolytic products produced by αS and that the 7 kDa product is essential to the
aggregation process of full-length αS, an assertion which was neither confirmed nor
refuted by this work due to the inability to isolate the 7 kDa fragment alone (Vlad and
colleagues had the fragment synthesized).74 They showed that the 7 kDa band
corresponds to αS residues 72-140, with the cleavage occurring in the central
amyloidogenic region of αS (61-93).
Mass spectrometry also proved the utility of the 7 kDa band in using MALDI-ToF
mass spectrometry to predict initial αS monomer concentration. The ratio of the intensity
of the 14 kDa peak to the 7 kDa peak proved to be an excellent predictor of initial
monomer concentration (as determined by UV spectroscopy). One potential explanation
is that the autoproteolysis reaction is zero order, which would make time the only factor
determining the amount of αS(72-140) produced. Higher monomer concentrations would,
therefore, not alter the rate of αS(72-140) production, leading to higher relative amounts
of monomer compared to autoproteolytic product. This was confirmed by the ability to
normalize the intensity of the 14 kDa peak for each concentration against that the 7 kDa
peak of that concentration by assuming that the 7 kDa peaks for all concentrations should
have the same, arbitrarily defined, intensity and obtain a linear curve when the adjusted
14 kDa peak intensities were plotted against initial monomer concentration. If the
relationship between the ratios of the 14 kDa and 7 kDa peak intensities for varying
concentrations was linear for a reason other than a constant concentration of the 7 kDa
peak, regardless of initial αS concentration, this would not have been the case. This
indirect evidence of the zero order nature of αS autoproteolysis can be further supported
through future kinetic experiments designed to determine the rate of αS degradation.
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CHAPTER V
α-SYNUCLEIN OLIGOMERS (DSOs)
The aggregation of amyloidogenic proteins plays an integral role in the
pathogenesis of neurodegenerative diseases such as PD and AD. The formation of
oligomeric species both on and off the canonical aggregation pathway is a potential cause
of neuronal toxicity. It is therefore essential that reliable methods of in vitro oligomer
preparation be developed in order to properly characterize and investigate oligomer
interactions. In this work, the author reports two methods of αS oligomer generation. In
the first, αS oligomers are induced by the neurotransmitter dopamine, isolated, and
characterized. Their mechanism of formation is also investigated. In the second, a nonesterified fatty acid (lauric acid; C12) is used as an oligomer inducer.
Results
Dopamine-derived α-Synuclein Oligomers (DSOs)
A 50 µM αS sample was incubated in the presence of 200 µM DA and 50 mM
NaCl at 37 °C with agitation for 72 h. The sample was spun down and an aliquot of the
supernatant was put aside for silver staining (Figure 13B, Lane P). The supernatant
showed a large smear ranging from ~7 to ~250 kDa, representing a broad range of αS
oligomers. The remainder of the supernatant was purified using SEC chromatography.
Following a small peak at the void volume, oligomeric αS eluted from fractions 17 to 23
(Figure 13A, dashed area), either in one broad peak or perhaps in two overlapping peaks.
Monomeric αS eluted from fractions 24 to 27. Oligomeric αS was subjected to SDSPAGE followed silver staining and western blotting. DSOs appeared to have eluted in
relatively discrete oligomeric assemblies of successively decreasing size (Figure 13B).
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Fractions 17 to 23 are seen in Lanes 1 to 7, respectively. The oligomeric band in fraction
17 ranged from ~110 to ~252 kDa, corresponding to 8 to 18mers (DSO8-18); fraction 18
ranged from ~70 to ~210 kDa, corresponding to 5 to 15mers (DSO5-15); fraction 19
ranged from ~56 to ~182 kDa, corresponding to 4 to 13mers (DSO4-13); fraction 20
ranged from ~42 to ~140 kDa, corresponding to 3 to 10mers (DSO3-10); fraction 21
ranged from ~33 to ~70 kDa, corresponding to 3 to 6mers (DSO3-6); fraction 22 ranged
from ~28 to ~56 kDa, corresponding to 2 to 5mers (DSO2-5); and fraction 23 ranged from
~28 to ~42 kDa, corresponding to 2 to 3mers (DSO2-3).

Figure 13. SEC and silver stain of DSOs. (A) SEC profile of DSOs. DSOs eluted from
fraction 17-23, indicated by the dashed line. (B) DSOs elute in a ladder of decreasing
MWs. Lane P shows DSOs prior to SEC fractionation, Lanes 1-7 show fractions 17-23,
respectively, stained with silver stain, and Lanes 8-12 show fractions 19-23, respectively,
after western blotting (representative of n = 10).
DLS analysis of DSOs. Due to the relative imprecision of gel electrophoresis as a
means of determining molecular size, DSOs were analyzed via DLS to determine whether
the stepwise size decrease observed in gel electrophoresis was reliable. DLS data was
averaged for 60 runs of 30 s for each sample. This relatively large number of
measurements was necessary due to the inherent polydispersity of the samples. Reliable
DLS data was obtained for DSO4-13, DSO3-10, DSO3-6, and DSO2-5 (Figure 14). DSO4-13
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exhibited the largest average diameter of 11.0 nm, followed by DSO3-10 with 10.3 nm,
DSO3-6 with 7.78 nm, and DSO2-5 with 4.88 nm.

Figure 14. DLS profiles of DSOs. Diameter of DSO4-13 (light grey), DSO3-10 (grey),
DSO3-6 (dark grey), and DSO2-5 (black).
Conformation of DSOs. Fractions 19-23 (DSO4-13 through DSO2-3) were analyzed
to determine secondary structural characteristics using CD spectroscopy. Fractions 17 and
18 (DSO8-18 and DSO5-15, respectively) were not concentrated enough to generate reliable
CD spectra. All analyzed oligomers showed CD spectra characteristic of random coil
structure, failing to exhibit any distinctive shift in secondary structure when compared to
monomeric αS. Figure 15 shows the combined spectra of all DSOs (dotted lines)
compared to the spectrum of fresh, monomeric αS (solid line).
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Figure 15. DSOs exhibit random coil secondary structure. DSOs (dotted lines) all share
similar random coil architecture, compared here to the random coil of fresh αS monomer
(solid line; n = 3).
ThT analysis of DSOs. In order to determine the propensity of DSOs to form
fibrils, aliquots of 1 µM DSOs in 20 mM Tris, pH 8.0 with 50 mM NaCl were kept at 37
°C for extended periods of time and assayed for any increase in ThT fluorescence (Figure
16). The ThT analysis did not include DSO8-18 or DSO5-15 due to their low concentrations.
DSO4-13 (■), DSO3-10 (◯), DSO3-6 (▲), DSO2-5 (▿), and DSO2-3 (●) all failed to show any
increase in ThT fluorescence over an extended period of 264 h.

Figure 16. DSOs are not ThT-positive and do not form ThT-positive aggregates over
time. DSO4-13 (■), DSO3-10 (◯), DSO3-6 (▲), DSO2-5 (▿), and DSO2-3 (●) failed to show
any increase in ThT fluorescence over 264 h (representative of n = 5)
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Temporal Stability of DSOs. Given the random coil nature of DSOs and their
failure to form ThT-positive aggregates over time, gel electrophoresis and silver staining
were used to determine whether or not they remained in their oligomeric assemblies, as
well. Figure 17 shows DSOs at 0, 72, and 240 h. Lanes 1, 2, 3, 4, 5, and 6 (irrespective of
time point) contain DSO4-13, DSO3-10, DSO3-6, DSO2-5, and DSO2-3, respectively. At 72 h,
no change whatsoever is detectable in oligomer size or intensity compared to the 0 h
sample, and there are no fibrils evident at the top of the gel. By 240 h, oligomer band
intensity decreased somewhat, and larger molecular weight bands could be seen at the top
of the gel indicative of some degree of large aggregate formation. In addition, it appeared
that the assembly size of DSO3-10 and DSO3-6 increased slightly.

Figure 17. DSOs are stable over extended periods of time. No difference was seen
between DSOs between 0 and 72 h, although by 240 h, they had started to form larger
aggregates. Lanes 1, 2, 3, 4, 5, and 6 contain DSO4-13, DSO3-10, DSO3-6, DSO2-5, and
DSO2-3, respectively (representative of n = 3).
Oxidation is necessary for the oligomerization of αS. In order to shed more light
on the mechanism by which dopamine promotes the oligomerization of αS, 50 µM αS
with 50 mM NaCl in 20 mM Tris was agitated at 37 °C with and without 5 mM Na2S2O3,
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both in aggregating conditions (no DA) and oligomerization conditions (with 200 µM
DA). After 24 h of incubation, the formation of higher order oligomers and aggregates of
αS in the absence of DA was not affected by the presence of the reducing agent Na2S2O3
(Lanes 1 and 2, with and without Na2S2O3, respectively). This trend continued to 72 h
(Lanes 1 and 2, with and without Na2S2O3, respectively), at which point the intensity of
bands at the top of the gel suggests significant formation of fibrils, confirmed by ThT
fluorescence (Figure 19). However, the formation of the higher order oligomers seen
when αS was incubated with DA for 24 h was inhibited in the presence of Na2S2O3
(Lanes 3 and 4, with and without Na2S2O3, respectively). This inhibition remained active
out to 72 h.

Figure 18. DSO formation is inhibited in the presence of Na2S2O3. Lanes 1 and 2 show
αS controls with and without Na2S2O3, respectively. Lanes 3 and 4 show DSO forming
conditions without and with Na2S2O3, respectively (representative of n = 3).
ThT of αS oxidation with and without Na2S2O3. The reaction shown in Figure 18,
above, was simultaneously monitored for increasing ThT fluorescence. Within 72 h, both
αS alone (■) and αS with Na2S2O3 (□) had formed ThT-positive aggregates, while αS
incubated with DA failed to form any such aggregates, whether in the absence (▲) or the
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presence ( ) of Na2S2O3 (Figure 19). Inhibition of ThT-positive aggregation by DA was
maintained out to 240 h, even in the presence of Na2S2O3.

Figure 19. DA inhibits the ThT-positive aggregation of αS. αS with (□) and without (■)
Na2S2O3 aggregated within 72 h, while DA-containing αS failed to aggregate over 240 h
whether with ( ) or without (▲)Na2S2O3 (representative of n = 3).
Dopamine oxidation. DA (300 µM) was incubated in 20 mM Tris, pH 8.0, with
agitation at 37 °C. A UV spectrum from 200-600 nm was collected at 0, 72, and 144 h
(Figure 20). Initially (solid line), the UV spectrum of DA exhibited a lone peak at 280
nm. By 72 h (dashed line), DA had oxidized, evidenced in the UV spectrum by an
increased baseline absorbance, along with a relative decrease in the intensity of the 280
nm peak, which corresponds to the formation of what may be a heavily obscured peak at
~320 nm. Continued monitoring of the oxidation of DA to 144 h (dotted line) showed the
potential peak at 320 nm becoming slightly more evident while the baseline absorbance
continued to increase.
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Figure 20. DA oxidation causes an absorbance shift and baseline increase. Fresh DA
(solid line) showed absorbance at 280 nm alone, while DA at 72 (dashed line) and 144
(dotted line) h showed increased baseline absorbance and the formation of a possible
peak at 320 nm, indicated by an arrow (representative of n = 3).
Fatty Acid Oligomers
Generation of fatty acid-derived αS oligomers. Both physiological and
experimental interfaces are known to affect the conformation and aggregation of amyloid
proteins.32,35,45,75,78-82 In work previously done in the author’s lab, micellar interfaces
generated around the critical micelle concentration of C12 non-esterified fatty acid were
utilized to push Aβ42 aggregation towards the formation of off-pathway oligomers.
Given the propensity of αS for lipid membranes,78 a similar procedure was followed for
αS. An aliquot of 50 µM αS was incubated for 48 h at 37 °C under quiescent conditions,
with and without 5 mM C12 in both 50 and 150 mM NaCl. Figure 21 shows 50 µM αS
incubated with 50 and 150 mM NaCl alone (Lanes 1 and 2) and 50 µM αS incubated with
5 mM C12 and 50 mM (Lane 3) or 150 mM (Lane 4) NaCl. Incubation with 50 mM,
rather than 150 mM NaCl, seems to promote the autoproteolytic degradation of αS into
smaller fragments (Lane 1 vs. Lane 2) as discussed in Chapter III. Even in the absence of
C12, a band was seen at approximately 37 kDa, possibly corresponding to an αS dimer.
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The presence of 5 mM C12 enhanced the formation of the 37 kDa oligomer while also
promoting the formation of an oligomer with an approximate molecular weight of 55
kDa, representing a trimer or tetramer (Lanes 3 and 4). The 55 kDa oligomer was more
apparent when αS was incubated with 50 mM NaCl (Lane 3). In addition, 5 mM C12
along with 50 mM NaCl promoted the retention of very large oligomeric or fibrillar
species that failed to enter the gel.

Figure 21. Formation of fatty-acid derived αS oligomers. Lanes 1 and 2 are αS controls
with 50 or 150 mM NaCl, respectively, while Lanes 3 and 4 contain 5 mM C12, along
with 50 or 150 mM NaCl, respectively. Dimeric and trimeric αS is visible in Lanes 3 and
4 (representative of n = 3).
Conclusions
DSO Formation and Characterization
The incubation of αS with DA has been previously shown to be a reliable method
for the production of large αS oligomers.38,46,70-72,83 In addition, previous work has shown
that they are isolable into relatively discrete units.69 It is noteworthy that large αS
oligomers, generated through a protocol similar to the one used in this work, inhibited
SNARE-mediated binding of lipid vesicles, showing a potential mechanism of DSO
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toxicity.38 The ability to separate DSOs into discrete species as demonstrated by Rekas
and co-workers is important,69 not only because it sheds some light into the composition
of the overall oligomeric ensemble formed through interaction with DA, but also because
it allows the elucidation of the potentially differing interactions that large and small
oligomeric assemblies might have with αS or other proteins. To that end, the oligomers
generated in this work have been thoroughly characterized through a variety of
biochemical and biophysical methods, leading to a greater understanding of their
structure, interactions, and mechanisms of formation.
The SEC fraction of DSOs resulted in a variety of discrete oligomers, similar to
what was previously observed.69 DLS measurements of the fractions confirmed the
overall size differences corresponding to the molecular weights observed by
immunoblotting, although the samples failed to display complete monodispersity.
Given the general pattern of amyloidogenic protein aggregation, it was expected
that aggregates would adopt a predominantly β-sheet conformation. However, even the
largest fraction measured (DSO4-13) retained random coil configuration nearly identical to
that of αS monomer. Recently, Illes-Toth and co-workers elucidated that between one and
three molecules of DA bind to each molecule of αS, and, more importantly, that DA only
binds αS when αS is in its extended state.72 It is possible that being locked into this
extended conformation via potential covalent adduct formation forces αS down an offpathway of aggregation.
Existing in such a conformationally locked state, αS oligomers may not adopt the
typical aggregation pathway towards fibrils, thus behaving as off-pathway species. The
off-pathway nature of DSOs was further supported through ThT fluorescence
experiments. ThT exhibits an increase in fluorescence upon a structural change occurring
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upon binding to β-sheet aggregates. The lack of substantial ThT fluorescence in DSOs,
whether freshly purified or incubated at 37 °C for 240 h, substantiates the idea that the
oligomeric structure may be in an extended, non β-sheet conformation as observed by
CD. In addition, DSOs remain stable at 4 °C for 72 h, with no conversion to higher
molecular weight species and no apparent dissociation to form monomeric αS. Only after
240 h of incubation did some larger order aggregates seem to. It may be noted that ThT
fluorescence remained low through 240 h, even at 37 °C, suggesting either that large
aggregate formation occurs in very small concentrations or that large aggregates are
formed through the eventual lateral association of DSOs, leading to larger aggregates that
remain ThT negative.
DSO Mechanism of Formation
Although a number of researchers have investigated the formation of αS
oligomers in the presence of DA, the mechanism of their formation has not yet been
completely elucidated. It is not even entirely clear whether or not DA associates with αS
covalently. Leong et al. suggested that the primary mechanism in the formation of DSOs
is the oxidation of the four methionine residues of αS, caused by the generation of
reactive oxygen species (ROS) during the oxidation of DA.84 Later research showed that
DSO formation can be partially reversed through the addition of copper (II) ion to the
solution, arguing against covalent modifiation.85 However, small angle X-ray scattering
experiments suggested that cross linking with polymerized DA stabilizes αS oligomers
and results in the prevention of β-sheet formation.69 Use of a staining method specific to
quinone-modified proteins suggested that polymerized DA interacts only with oligomeric
αS species and not monomers.71 The same work showed via ESI-MS that incubation of
αS monomer with DA did not result in the formation of monomer-DA adducts. Taken
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together, it is possible that DA oxidation, which occurs readily, promotes the oxidation of
αS methionine residues, which in turn leads to the formation of αS oligomers. Those αS
oligomers may then be stabilized through cross-linking with oxidized DA-quinone
polymer.
To provide some measure of additional insight into this question, Na2S2O3 was
incubated along with αS and DA to observe its effect on DSO formation. Na2S2O3 is
known to reduce quinones86 and so should prevent the formation of DA-quinones.
Na2S2O3 has never been reported to be capable of reducing sulfoxides, however, so it may
not be able to prevent the oxidation of methionine sulfoxides formed in αS. Incubating αS
and DA in the presence of Na2S2O3, therefore, should have largely prevented the
formation of DA-quinones, which would have been unable to associate with αS. Should
the formation of DA-quinones cause the oxidation of methionine residues, as suggested
by Leong et al.84, the presence of Na2S2O3 would also inhibit the oxidation of αS to some
degree, even if Na2S2O3 alone is not capable of reducing sulfoxide moieties. However,
the substantial difference seen in the oligomeric content between control αS and αS
incubated with Na2S2O3 in the absence of DA suggests that αS oligomer generation along
the fibril formation pathway is also inhibited in the presence of Na2S2O3. It is possible
that Na2S2O3 prevents the formation of methionine sulfoxide residues, which has been
shown to be sufficient to generate αS oligomers84. Alternately, Na2S2O3 may be
preventing an alternate type of oligomer-inducing oxidative process, such as the
formation of o,o’-dityrosine, which has been demonstrated to form stable, large order
oligomers in αS and is increased in the brains of PD-model mice.87,88 Interestingly, ThT
profiles showed that αS aggregated more quickly in the presence of Na2S2O3 than it did
alone, suggesting that the formation of αS oligomers mediated by their oxidation may
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compete with the fibril formation pathway, even in the absence of DA. When αS in the
presence of DA was incubated with and without Na2S2O3, Na2S2O3 was seen to
completely inhibit the formation of DSOs. However, it was unable to completely rescue
ThT fluorescence, suggesting that the formation of fibrils was inhibited as well. Clearly
the presence of Na2S2O3 does not inhibit fibrils, so the presence of DA must have caused
the inhibition. However, the oligomer forming action of DA seemed to be completely
prevented, and the presence of Na2S2O3 should have prevented any oxidation, suggesting
perhaps that DA is able to prevent fibril formation even without oxidizing to form DAquinones, although the mechanism whereby this could occur is unclear. However, it is
apparent that the oxidation of DA is required for the formation of DSOs.
Fatty Acid-derived Oligomers
As has been mentioned, previous work in the author’s lab resulted in the
successful generation of a stable Aβ42 oligomeric species known as LFAOs in the
presence of fatty acid interfaces.43 Biological interfaces are known to affect the
aggregation of Aβ and αS, promoting the formation of oligomers under certain
conditions.32,35,45,75,78-82 The formation of LFAOs is promoted by the incubation of
monomeric Aβ42 with the non-esterified fatty acid C12 (lauric acid) at concentrations of
C12 near to its critical micelle concentration. The interaction of Aβ42 with the micelle
surface leads to the formation of relatively discrete LFAOs, which are isolable via SEC.
Incubation of αS in a similar concentration of C12, promoted the formation of SDSresistant trimers, although the majority of protein remained in a monomeric or dimeric
state after 72 h of incubation. It is known that αS adopts a helical conformation upon
binding to lipid membranes, and it is possible that this conversion to some extent prevents
the formation of oligomeric species. It is possible that more optimal conditions could be
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developed to promote the formation of isolable αS oligomers through interactions with
fatty acid interfaces, and this will be a topic of future work.
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CHAPTER VI
SELF-PROPAGATION OF DSOs
Self-propagation in a prion-type fashion provides a potential mechanism for the
extent of toxicity seen in neurodegenerative diseases. Toxic oligomeric species capable of
propagating their misfolded conformation can potentially produce a regenerative well of
toxicity; even though oligomeric species may be transferred eventually to the kinetic sink
of fibrillization, propagation while in the oligomeric state would result in no net reduction
of oligomer concentration. In this chapter, the self-propagative capacity of DSOs is
examined in an attempt to determine whether they are capable of converting monomeric
αS into DSO-like aggregates.
Results
DSOs Self-propagate
αS (50 µM) was incubated at 37 °C in quiescent conditions alone and with 0.1 µM
DSO4-13 through DSO2-5. Figure 22 shows this reaction at 72 h (A) and 144 h (B). Lane 1
in both A and B is the αS control, while lanes 2, 3, 4, 5, and 6 are DSO4-13, DSO3-10,
DSO3-6, DSO2-5, and DSO2-3. Lanes 7-11 are DSO controls corresponding to lanes 2-6,
respectively. An increase in the amount of oligomeric αS compared to the control is
evident for samples containing DSO4-13, DSO3-10, and DSO3-6 at 72 h. The intensity of
each of these oligomeric bands is also significantly higher than their corresponding
controls. The increase in oligomeric content compared to control αS is even more evident
at 144 h, at which point samples containing DSO4-13, DSO3-10, DSO3-6, and DSO2-5 all
show greater intensity of the oligomeric band. Once again, the amount of oligomer
present is significantly higher than control DSOs, which are not even visible at the
exposure level of this western blot. In addition, the oligomeric bands formed in DSO
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containing samples correspond to the molecular weight of their respective DSO. DSO2-3
seemed to push αS away from its monomeric state, but a clear oligomeric or fibrillar band
was not visible to determine the molecular weight of any assemblies formed.

Figure 22. DSOs self-propagate with monomeric αS. Lanes 2-6 contain αS incubated
with DSO4-13, DSO3-10, DSO3-6, DSO2-5, and DSO2-3, respectively, while lanes 7-11
contain equivalent amounts of DSO in the absence of αS at 72 h (A) or at 144 h (B).
There is an increase in oligomeric content compared to the αS control (Lane 1) in Lanes
2-4 at 72 h and Lanes 2-5 at 144 h. Oligomeric bands also exhibit greater intensity than
their respective controls at both 72 and 144 h (representative of n = 5).
DSOs Do Not Promote ThT-positive Aggregation
Along with their western blotting, self-propagation reactions with αS were
monitored for ThT fluorescence. At the concentration and conditions used for this
reaction, specifically 50 µM under quiescent conditions, control αS did not aggregate
within 312 h. The same lack of aggregation was seen in all of the DSO-seeded samples,
in spite of the formation of the oligomeric species seen in western blots. Indeed, their
level of ThT fluorescence consistently remained slightly below that of the αS control
(Figure 23).
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Figure 23. DSOs do not seed ThT-positive αS aggregation. Neither αS controls nor αS
incubated with DSOs aggregated within 312 h (representative of n = 5). Aggregation
profile of αS control (■) and αS with DSO4-13 (▲), DSO3-10 (▿), DSO3-6 (⬥), DSO2-5 (◁),
DSO2-3 (▸︎).
Conclusions
The results clearly indicate that DSOs are capable of self-propagation, which is
likely by virtue of their being conformationally distinct. To the author’s knowledge, this
is the first described case of self-propagation of an amyloid protein in which the parent
species does not adopt and propagate significant β-sheet conformation, possibly due to
the formation of αS-DA adducts. It is not entirely clear how DSOs propagate their
oligomeric state. Even if they are originally formed as adducts through cross-linking by
DA-quinone multimers, such cross-linking could not be their mechanism of propagation
due to the lack of free DA in propagation reactions. Similarly the oxidation of monomeric
αS methionine residues seems unlikely to play a major role, given the lack of oxidative
conditions. A likely mechanism is that the DSOs serve as a corruptive template, with the
established stability of their extended, cross-linked structure serving to promote the
conversion of monomeric αS to a similar structure. In this case, newly formed DSO
daughters (DSOD) would be non-covalently associated and possibly less stable than
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parent DSOs (DSOP. Future work will address these and other questions, including
whether or not DSOs are capable of cyclic amplification similar to mammalian prion
proteins.
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CHAPTER VII
CROSS-PROPAGATION OF DSOs
The primary goal of this work is to establish a mechanistic link between the
principal pathological events seen in PD and AD, namely the toxic oligomerization of αS
and Aβ42, respectively. Towards that goal, having shown that DSOs have the ability to
self-propagate, their cross-propagative properties were also investigated. Should DSOs
prove capable of propagating their oligomeric state to monomeric Aβ42 in vitro, it is
possible that a similar mechanism may form the basis of the cross-pathologies between
PD and AD.
Results
DSOs Promote the Formation of Aβ42 Oligomers
Monomeric Aβ42 (15 µM) was incubated with and without DSOs (1 µM)
quiescent at 37 °C in 20 mM Tris, pH 8.0, with 50 mM NaCl and 0.01% NaN3. After 72 h
of incubation, samples were subjected to SDS-PAGE and western blotted with Ab5 antiAβ antibody (Figure 24). Lane C shows an Aβ42 control with no DSO, while lanes 1-5
show Aβ42 with DSO4-13, DSO3-10, DSO3-6, DSO2-5, and DSO2-3, respectively. Samples
incubated with DSO show a stark contrast compared to the control, with a distinct
oligomeric band forming with an approximate molecular weight of 160 to >260 kDa. The
two smaller oligomers, DSO2-5 and DSO2-3 in particular seem to strongly promote
oligomer formation, with DSO2-3 causing an apparent decrease in the amount of large
protofibrils or fibrils that failed to enter the gel, as well. In addition, the larger oligomers
(DSO4-13, DSO3-10, and DSO3-6) seem to promote the formation of what may be Aβ42
trimers. Although DSOs were not able to propagate their particular molecular weights, it
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is clear that their interaction with Aβ42 promotes the formation or retention of oligomeric
Aβ species.
DSOs Delay and Reduce the ThT-positive Aggregation of Aβ42
Along with western blotting, reactions with Aβ42 and DSO were monitored daily
for ThT fluorescence (Figure 26). The aggregation of the Aβ42 control (◃) followed a
typical sigmoidal growth pattern with a lag time of approximately 72 h, while incubations
with DSOs showed significantly decreased total fluorescence and/or extended lag times.
The incubation with DSO4-13 (■) showed the most marked increase in fluorescence, with

Figure 24. DSOs promote the formation of Aβ42 oligomers. Lane C shows Aβ42
incubated at 37 °C in the absence of DSO. Lanes 1-5 show DSO4-13, DSO3-10, DSO3-6,
DSO2-5, and DSO2-3, respectively. DSOs clearly promote the formation of an oligomeric
band ranging from ~160 to >260 kDa (~35 to >57mers), along with the slight formation
of trimers in the case of show DSO4-13, DSO3-10, and DSO3-6 (representative of n = 5).
a lag time similar to the Aβ42 control. Aβ42 incubated with DSO3-6 (▲) also had a
similar lag time to the control, but its total fluorescence increase was lower than the
incubation with DSO4-13. Aβ42 incubations with DSO3-10 (◯), DSO2-5 (▿), and DSO2-3
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(

) all exhibited decreased lag times and minimal increases in fluorescence intensity. It

is evident, therefore, that DSOs promote the formation of ThT-negative Aβ42 oligomers
while simultaneously inhibiting the formation of fibrils or other ThT-positive Aβ42
aggregates.

Figure 25. DSOs inhibit the ThT-positive aggregation of Aβ42. 15 µM Aβ42 was
incubated with 1 µM DSO4-13 (■), DSO3-10 (◯),DSO3-6 (▲), DSO2-5 (▿), or DSO2-3 ( ).
All incubations with DSO exhibited significantly less fluorescence over time than the
Aβ42 control (representative of n = 5).
Conclusions
It is clear that DSOs have the capacity to promote the formation of oligomers
from monomeric Aβ42. The presence of oligomeric Aβ42 in the samples incubated in the
presence of DSOs but not control Aβ42 is ample evidence of such an interaction.
However, it is not clear whether true cross-propagation is occurring. Although the
oligomeric state is being transmitted from DSOs to Aβ42, it seems as though all DSOs
promote a similar molecular weight Aβ42 oligomer, rather than a range of oligomers
corresponding to the size of the parent DSO, as was seen with DSOs self-propagation. It
is possible that only a particular oligomeric conformation of Aβ42 is capable of
interacting with the DSO structure, regardless of its size. Importantly, though, formation
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of oligomers occurs during the lag phase of Aβ42 aggregation, and the presence of DSOs
seems to delay and reduce the eventual aggregation of DSO-containing samples. This
lack of conventional “seeding”—causing a decrease in the lag time required for
aggregation to occur—in spite of the formation of oligomeric species suggests that the
oligomers formed are ThT-negative, off-pathway oligomers, adopting a different
conformation from on-pathway oligomers and fibrils. This may be due to the ThTnegative state of the parent DSOs, in which case some measure of conformational crosspropagation may be occurring. Future experiments will be pursued to determine the
longevity of these oligomers and their potential for isolation. If isolable, the ability of
these propagated Aβ42 oligomers to recruit more Aβ42 or αS monomer into an
oligomeric state would be an important topic of investigation. The capacity of DSOs to
cause Aβ42 oligomer formation already provides a concrete link between PD and AD
pathology at the molecular level; if Aβ42 oligomers formed in this fashion were able to
then propagate in turn, it would provide further evidence that these two diseases can exist
in a vicious cycle of cooperative degeneration.
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CHAPTER VIII
CROSS-PROPAGATION OF LFAOs WITH α-SYNUCLEIN
There is no reason cross-propagation should only flow in one direction. Indeed,
given the relative promiscuity of amyloid cross-seeding, it seems unlikely that it would.
LFAOs are stable Aβ42 oligomers that have previously been shown to possess the
capacity for self-propagation.54 Unpublished work in the author’s lab also suggests that
LFAOs are capable of cross-propagating their oligomeric state to various mutants of
Aβ42, as well as to its less pathogenic isoform, Aβ40. Therefore, LFAOs were chosen as
a model Aβ42 oligomer system to investigate potential cross-propagation with αS
monomer.
Results
LFAOs Promote the Formation of αS Oligomers
αS (10 µM) was incubated with 5, 2.5, and 1 µM LFAO, agitated at 37 °C for 72
h. Oligomer formation was visualized with both Ab5 and Syn211 western blots. Figure
26 shows αS with 5 µM LFAO (Lanes 1 and 7), 2.5 µM LFAO (Lanes 2 and 8), and 1 µM
LFAO (Lanes 3 and 9), along with an αS control (Lane 6). Lane 4 is a 2.5 µM LFAO
control, and Lane 3 is a 1 µM LFAO control. The Ab5 blot shows that the presence of αS
monomer promoted the retention of LFAO in an oligomeric state, as comparison of 2.5
and 1 µM LFAO in the samples with and without αS (Lanes 2 and 3 vs. Lanes 4 and 5)
shows. In addition, the presence of LFAO promoted the formation of αS oligomers, as
can be seen in in the Syn211 western blot for 5 and 2.5 µM LFAO (dashed box).
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Figure 26. LFAOs promote the formation of αS oligomers, while αS monomer prevents
LFAOs from going on to form fibrils. 10 µM αS with 5 (Lanes 1 and 7), 2.5 (Lanes 2 and
8), or 1 (Lanes 3 and 9) µM LFAO. Lanes 4 and 5 are 2.5 and 1 µM LFAO controls,
respectively (representative of n = 3).
Conclusions
It is quite clear that LFAOs are capable of promoting the oligomerization of αS
monomer. However, as was also seen in the cross-propagation of DSOs to Aβ42
monomer, the oligomeric daughter is not of the same molecular weight as the parent
oligomer. However, analysis of molecular weights suggests that the number of monomer
units incorporated into the oligomeric assemblies may actually be quite similar. LFAOs
have a molecular weight between ~55-80 kDa, suggesting that they comprise 12-18mers.
For αS, a similar range of 12-18mers would result in a molecular weight range of ~175260 kDa, which is very near to the molecular weight actually observed. In addition to the
ability of LFAOs to promote the oligomerization of αS monomer, it also appeared as
though αS prevented the aggregation of LFAOs, even under the intense fibrillization
conditions used in these experiments (37 °C with agitation and salt). It is possible that
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this stabilization occurs through association of monomeric αS with the LFAO
superstructure and that this interaction may lead to the conversion of those monomers to
oligomeric assemblies. It seems, therefore, that not only do LFAOs cross-propagate to
αS, enhancing the formation of potentially toxic oligomeric species, but also that the
presence of αS promotes the retention of Aβ42 in this off-pathway oligomeric form.
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CHAPTER IX
DISCUSSION AND IMPLICATIONS
It is clear that the old way of thinking about and investigating neurodegenerative
diseases as a disparate collection of pathologies has ended. The evidence presented in this
work, along with numerous papers published in the past decade, show without ambiguity
that amyloidogenic proteins can and do interact and influence each other’s aggregation
both in living and experimental systems.2,49,55,56,58,61-64,66-68,89 The commonality among the
underlying aggregation mechanisms for amyloid proteins appears to provide a rich
substrate for interaction, one that, unfortunately, leads to numerous unfavorable
interactions between neurodegenerative proteins. Going forward, it will be critical for the
amyloid research community to quantify and catalogue this bewildering variety of
potential interplay between these proteins. In addition, treatments geared toward affecting
the aggregation of any particular amyloid protein should be evaluated for their potential
effect on others, as well; although the similarities between amyloids may cause cascading
cycles of disease, they may also enable the amelioration of multiple pathologies by
manipulating a single target.
The work presented here is the first published evidence of oligomeric crosspropagation between neurodegenerative proteins. Critically, such an interaction provides
a molecular mechanism explaining the pathogenic link between PD and AD. Although
cross seeding between αS and Aβ42 had been previously generated,68 the shift towards
viewing oligomers as the primary toxic species in both PD and AD meant that crossseeding of fibril formation was not enough to explain the increased severity and neuronal
death seen in cases exhibiting cross-pathology. However, the ability of soluble, toxic
oligomers of both αS and Aβ42 to both self-propagate and promote the formation of
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complementary oligomers would lead to a pernicious source of continual toxicity, in
which normal, functional monomers of either protein could be corrupted into an
oligomeric form, which could then recruit more monomers and so on. Of course, one
must wonder, if this is the case, why the process does not continue ad inifinitum, until all
available protein is in the oligomeric state. The relative transience of even off-pathway
oligomers, combined with the thermodynamic stability of fibrils, however, provides a
ready answer. Oligomeric species have a definite half-life, whether they go on to form
fibrils or dissociate into their monomeric subunits.53,90 Therefore, while they may be
capable of replenishing their pool through self-propagation, they eventually will proceed
to the extremely stable thermodynamic sink of fibrils or dissociate to form monomers.
However, it is important to note that this logic applies only within a given protein. Crosspropagation has the potential to generate entirely new populations of oligomeric species,
which, through their own self-propagation, may generate another self-sustaining pool,
increasing overall neuronal toxicity and being a potential cause for the more severe
disease progression seen with combined pathologies.
In addition to exploring the interactions between oligomeric species of different
proteins, this work characterized dopamine-derived αS oligomers extensively. These
DSOs were shown to be stable, off-pathway species that, strangely, adopted no specific
secondary structure, perhaps due to the stabilizing factors contributed by their interaction
with dopamine. Importantly, DSOs were demonstrated to be easily isolable, allowing for
future in-depth investigations into interactional and pathological differences between
different sizes of DSOs. Isolated DSOs were shown to self-propagate, generating
oligomeric species of the same molecular weight from fresh αS monomer. Given the
cellular co-localization of DA and αS in post-synaptic neurites, the potential
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physiological relevance of DSOs is high. Work by another group has shown that DSOs
are capable of inhibiting SNARE-mediated lipid vesicle docking in vitro, demonstrating
one potential route for the toxicity of these oligomers.38 Given the physiological
relevance and potential toxicity of DSOs, their stability and capacity for self-propagation
may prove to be a major component of the pathway leading to neuronal death in PD,
particularly in the dopamine-rich substantia nigra. This and other work suggests that the
mechanism of DSO formation is closely linked to the oxidation of both DA and,
consequently, αS, insinuating that oxidative damage caused by ROS may be a factor in
the development of PD.
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CHAPTER X
FUTURE DIRECTIONS
Going forward, this work provides a cornucopia of potentially fruitful areas of
investigation. The characterization of the properties of DSOs is far from complete. For
example, their stability, although demonstrated in quiescent conditions at 4 and 37 °C,
should be investigated under a variety of conditions to determine whether or not they are
capable of producing β-sheet rich fibrils. In addition, previous research suggests that their
oligomerization may be partially reversed in the presence of copper (II) ion.85 If this is the
case, the interaction of DSOs with other physiologically relevant metal ions will be
critical to understand. It is also still unclear exactly how many monomeric units are
incorporated into a given DSO and whether certain aggregation numbers exhibit
increased stability compared to others. Interestingly, in spite of a relatively concentrated
research effort, the mechanism of DSO formation remains elusive. Attempts to resolve
the number of DA molecules incorporated within DSOs, or indeed whether they are
incorporated at all, have provided conflicting results. Detailed studies using advanced
methods of mass spectrometry may be necessary to obtain a concrete answer. In addition,
to the author’s knowledge, no experiments have yet been done investigating whether the
various pathologic mutations of αS increase or decrease its ability to form DSOs.
The self- and cross- propagation of DSOs also suggests future avenues of
experimentation. Experiments to determine whether or not DSOs are capable of
propagating to mutant isoforms of αS should be relatively straightforward, as should
experiments to determine whether or not they are capable of cross-propagating to other
neurodegenerative proteins, as well as varying mutants and isoforms of Aβ. More
complicated, but no less important will be studies to determine the nature of daughter
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oligomers. If possible, they should be isolated so that their structural features can be
compared to those of parent oligomers in detail, to determine the extent of the fidelity in
the cross-propagation process. In addition, the propagation capacity of this second
generation of oligomers should be determined.
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